3-(5-氯甲基-[1,2,4]噁二唑-3-基)吡啶 | 15328-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(5-氯甲基-[1,2,4]噁二唑-3-基)吡啶
• 中文别名: 3-[5-(氯甲基)-1,2,4-氧杂二唑-3-基]吡啶
• 英文名称: 5-(chloromethyl)-3-(pyridin-3-yl)-1,2,4-oxadiazole
• 英文别名: 3-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine；5-(chloromethyl)-3-pyridin-3-yl-1,2,4-oxadiazole
• CAS: 15328-03-7
• 化学式: C₈H₆ClN₃O
• mdl: MFCD00264506
• 分子量: 195.608
• InChiKey: RGRRKYQLLSVYGV-UHFFFAOYSA-N

物化性质

• 沸点：
  350.3±52.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H318
• 危险性防范说明：
  P280,P305 + P351 + P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-[5-(Chloromethyl)-1,2,4-Oxadiazol-3-Yl]Pyridine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H302 Harmful if swallowed.
H318 Causes serious eye damage.
Precautionary statement(s)
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 195,61 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-[5-(Chloromethyl)-1,2,4-Oxadiazol-3-Yl]Pyridine
Acute Tox. 4; Eye Dam. 1; <= 100 %
H302, H318
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-[5-(Chloromethyl)-1,2,4-Oxadiazol-3-Yl]Pyridine
Xn, R22R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Dam. Serious eye damage
H302 Harmful if swallowed.
H318 Causes serious eye damage.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R41 Risk of serious damage to eyes.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-(5-氯甲基-[1,2,4]噁二唑-3-基)吡啶 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.75h， 生成 2-(4-chlorophenoxy)-N-propan-2-yl-N-[(3-pyridin-3-yl-1,2,4-oxadiazol-5-yl)methyl]acetamide
  参考文献：
  名称：

  恶二唑-异丙基酰胺作为有效的非共价蛋白酶体抑制剂

  摘要：

  对 50 000 ChemBridge 化合物库的筛选导致鉴定出恶二唑-异丙基酰胺1 (PI-1833)，其抑制胰凝乳蛋白酶样 (CT-L) 活性（IC 50 = 0.60 μM），对其他两种主要蛋白酶体几乎没有影响蛋白水解活性，胰蛋白酶样 (TL) 和谷氨酰肽水解样 (PGPH-L)。LC-MS/MS 和透析表明1是一种非共价且快速可逆的 CT-L 抑制剂。集中文库合成为11ad (PI-1840) 提供了 CT-L 活性 (IC 50= 27 纳米）。详细的 SAR 研究表明酰胺部分和两个苯环对修饰敏感。疏水性残基，如在对位丙基或丁基（未邻位或间位）的A环和一个的米-吡啶基团作为B环，显著提高活性。化合物11ad (IC 50 = 0.37 μM)在抑制完整 MDA-MB-468 人乳腺癌细胞中的 CT-L 活性和抑制其存活方面比1 (IC 50 = 3.5 μM)更有效。11ad的活

  DOI：

  10.1021/jm400221d
• 作为产物：
  描述：

  3-氰基吡啶 在 盐酸羟胺 、 sodium carbonate 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 反应 14.5h， 生成 3-(5-氯甲基-[1,2,4]噁二唑-3-基)吡啶
  参考文献：
  名称：

  一种新型 1,2,4-恶二唑衍生物在体外和 3×Tg 小鼠中的合成和生物活性评价

  摘要：

  目的：阿尔茨海默病（AD）是最常见的神经退行性疾病，患者患有认知障碍。在我们的研究中，合成了一种新型的 1,2,4-恶二唑衍生物 wyc-7-20，它在细胞水平上表现出低细胞毒性和有效的神经保护作用。在 wyc-7-20 治疗后，在转基因动物模型中检测到改善的认知障碍、β-淀粉样蛋白 (Aβ) 清除和 tau 病理表型。还检测到 AD 相关基因的反向表达。结果表明 wyc-7-20 在 AD 治疗中是有效的。 目的：AD的病理复杂性增加了医学研究的难度。为了探索治疗 AD 的新的潜在药物，设计、合成了一种新型 1,2,4-恶二唑衍生物 (wyc-7-20)，以探索在本研究中的应用。 材料与方法：人神经母细胞瘤（SH-SY5Y）细胞和人肝细胞癌（HepG2）细胞用于检测中位致死剂量（LD50）。H 2 O 2和 Aβ 1– 42将寡聚体（AβOs）分别添加到SH-SY5Y细胞中以检测wyc-

  DOI：

  10.2147/dddt.s372750

文献信息

• Copper-catalyzed sp3-sp3 cross-coupling of turbo grignards with benzyl halides
  作者：Greg Petruncio、Synah Elahi-Mohassel、Michael Girgis、Mikell Paige

  DOI：10.1016/j.tetlet.2021.153516

  日期：2021.12

  benzyl halides and sulfonates imparts unique reactivity at the benzylic carbon atom. Photoredox sp3-sp3 cross-coupling proved ineffective for coupling p-methoxybenzyl chloride (PMBCl), leading to a new strategy for the sp3-sp3 cross-coupling of benzyl halides and sulfonates. This strategy involved LiCl-accelerated synthesis of a Grignard reagent followed by a copper-catalyzed cross-coupling. The conditions

  苄基卤化物和磺酸盐中的芳环赋予苄基碳原子独特的反应性。Photoredox sp 3 -sp 3交叉偶联被证明对偶联对甲氧基苄基氯 (PMBCl)无效，导致了苄基卤化物和磺酸盐的 sp 3 -sp 3交叉偶联的新策略。该策略涉及 LiCl 加速格氏试剂的合成，然后是铜催化的交叉偶联。由于 PMBCl 的特殊反应性，该条件对 PMBCl 工作良好，但其他苄基溴或磺酸盐反应不佳。
• Studies on the Synthese of N-Heterocyclic Compounds. III. Hypocholesterolemic 1, 2, 4-Oxadiazole Derivatives (1)
  作者：SHOJIRO YURUGI、AKIO MIYAKE、TOMIYOSHI FUSHIMI、EIKO IMAMIYA、HARUKI MATSUMURA、YOSHIO IMAI

  DOI：10.1248/cpb.21.1641

  日期：——

  3, 5-Disubstituted-1, 2, 4-oxadiazole derivatives containing aryl heteryl substituent at 3 position and amino, mercapto, aryl and heteryl substituent at 5 position have been synthesized. Among these compounds, 3-[4-(1-ethoxycarbonyl-1-methylethoxy)phenyl]-3-(3-pyridyl)-1, 2, 4-oxadiazole exhibited a considerable hypocholesterolemic activity.

  含有芳基杂原子取代基在3位和氨基、巯基、芳基及杂原子取代基在5位的3,5-二取代-1,2,4-噁二唑衍生物已被合成。在这些化合物中，3-[4-(1-乙氧羰基-1-甲基乙氧基)苯基]-3-(3-吡啶基)-1,2,4-噁二唑表现出显著的降胆固醇活性。
• HIV reverse transcriptase inhibitors
  申请人：Saggar A. Sandeep

  公开号：US20070021442A1

  公开（公告）日：2007-01-25

  Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R 1 and R 2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  具有以下结构的化合物：是HIV逆转录酶抑制剂，其中A、X、Y、Z、R1和R2在此处定义。这些化合物及其药用盐在抑制HIV逆转录酶、预防和治疗HIV感染以及预防、延缓AIDS发病和治疗方面具有用途。这些化合物及其盐可作为药物组成部分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors
  作者：Yajun Yang、Ke Wang、Bo Wu、Ying Yang、Fangfang Lai、Xiaoguang Chen、Zhiyan Xiao

  DOI：10.1016/j.bmcl.2020.127508

  日期：2020.11

  and synthesized based on the known proteasome inhibitor PI-1840. Most of them showed significant inhibition against the β5c subunit of human 20S proteasome, and five of them exhibited IC50 values at the sub-micromolar level, which were comparable to or even more potent than PI-1840. The most active two (1c and 1d) showed IC50 values of 0.12 and 0.18 μM against the β5c subunit, respectively, while they

  基于已知的蛋白酶体抑制剂PI-1840设计并合成了三十种新型三芳基化合物。它们中的大多数显示出对人20S蛋白酶体β5c亚基的显着抑制作用，并且其中五种在亚微摩尔水平显示出IC 50值，与PI-1840相当甚至更高。最活跃的两个（1c和1d）对β5c亚基的IC 50值分别为0.12和0.18μM，而对β2c，β1c和β5i亚基没有明显的抑制作用。分子对接为亚基选择性提供了有益的线索。本文鉴定的有效和亚基选择性蛋白酶体抑制剂代表了用于进一步分子优化的新化学模板。
• [EN] INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A<br/>[FR] INHIBITEURS CIBLANT LA GRIPPE A PHARMACORÉSISTANTE
  申请人：UNIV PENNSYLVANIA

  公开号：WO2013086131A1

  公开（公告）日：2013-06-13

  Provided are compounds according to formula (la) or (lb) as described herein, that are capable of modulating the activity of influenza viruses (e.g., influenza A virus), for example, via interaction with the M2 transmembrane protein, and other similar viroporins. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds according to according to formulas (la') or (lb), as described herein.

  根据本文描述的公式（la）或（lb），提供了一些化合物，这些化合物能够调节流感病毒（例如流感A病毒）的活性，例如通过与M2跨膜蛋白以及其他类似的病毒孔蛋白相互作用。还提供了一种治疗流感A感染疾病状态或感染的方法，包括通过给予包含根据本文描述的公式（la'）或（lb）的一个或多个化合物的组合物进行治疗。